ABSTRACT
ABSTRACT Objective We evaluated the prevalence of glutamic acid decarboxylase (GADA) and tyrosine phosphatase-protein antibodies (IA2A), their titers and their relation to first phase insulin response (FPIR) and glucose tolerance in autoimmune thyroid diseases (ATDs) patients. Subjects and methods Graves' disease (GD; n = 181) and Hashimoto's thyroiditis (HT; n = 143) patients in addition to healthy controls (n = 93) were studied. Secondly, FPIR and oral glucose tolerance tests (OGTT) were performed in 11 anti-pancreatic islet-cell (+) and in 20 anti-pancreatic-cell (-) patients. Results There was a non significant trend for higher prevalence of GADA positivity in GD vs HT (7.2% vs 2% p = 0.06), but the GADA titers were higher in HT. We also did not find a significant difference in IA2 prevalence (0.7% vs 0.0%) between these two groups or compared to the control group. In the subsequent analysis, low FPIR was found in 10% of these patients but without statistical difference for OGTT between pancreatic antibody-positive and -negative patients. Conclusion A trend for greater prevalence of GADA was observed for GD patients than for HT or control. However, the titers of these autoantibodies were higher in HT patients, but there was no significant relation to insulin secretion and glucose tolerance at that moment and stage of autoimmune diseases.
Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Autoantibodies/analysis , Blood Glucose/analysis , Graves Disease/enzymology , Protein Tyrosine Phosphatases/immunology , Hashimoto Disease/enzymology , Glutamate Decarboxylase/immunology , Insulin/metabolism , Graves Disease/blood , Protein Tyrosine Phosphatases/blood , Hashimoto Disease/blood , Insulin Secretion , Glucose Tolerance Test , Glutamate Decarboxylase/blood , Insulin/bloodABSTRACT
Type 1 diabetes, as an autoimmune disease, presents several islet cell-specific autoantibodies such as islet cell antibody (ICA), anti-insulin, anti-glutamic acid decarboxylase (GAD) and the antibody (Ab) against tyrosine phosphatase (PTP)-like protein known as ICA-512 (IA-2). In order to determine the frequency of the anti-GAD and anti-IA-2 autoantibodies in Brazilian type 1 diabetes patients we studied 35 diabetes mellitus (DM) type 1 patients with recent-onset disease 12 months and 37 type 1 diabetes patients with long-duration diabetes 12 months who were compared to 12 children with normal fasting glucose. Anti-GAD65 and anti-IA-2 autoantibodies were detected with commercial immunoprecipitation assays. The frequency of positive results in recent-onset DM type 1 patients was 80.0 percent for GADAb, 62.9 percent for IA-2Ab and 82.9 percent for GADAb and/or IA-2Ab. The long-duration type 1 diabetes subjects presented frequencies of 54.1 percent for GADAb and IA-2Ab, and 67.5 percent for GAD and/or IA-2 antibodies. The control group showed no positive cases. Anti-GAD and IA-2 assays showed a high frequency of positivity in these Brazilian type 1 diabetes patients, who presented the same prevalence as a Caucasian population
Subject(s)
Female , Humans , Child , Adolescent , Autoantibodies/blood , Diabetes Mellitus, Type 1/immunology , Glutamate Decarboxylase/blood , Insulin Antibodies/blood , Islets of Langerhans/immunology , Protein Tyrosine Phosphatases/blood , Brazil , Diabetes Mellitus, Type 1/blood , RadioimmunoassayABSTRACT
Reportamos la formación de agregados plaquetarios en ratones inyectados con el aminoácido fosfotirosina. Estos agregados se observaron en cortes histológicos de vasos sanguíneos, en sangre y en plasma enriquecido en plaquetas. La detección de un electrocardiograma alterado, junto a observaciones anteriores realizadas en plaquetas humanas, hacen sugerir que fosfotirosina libre podría tener un rol significativo en el proceso de activación plaquetario